A novel methylation signature predicts radiotherapy sensitivity in glioma
Abstract Glioblastoma (GBM) is the most common and malignant cancer of the central nervous system, and radiotherapy is widely applied in GBM treatment; however, the sensitivity to radiotherapy varies in different patients. To solve this clinical dilemma, a radiosensitivity prediction signature was c...
Guardado en:
Autores principales: | Yuemei Feng, Guanzhang Li, Zhongfang Shi, Xu Yan, Zhiliang Wang, Haoyu Jiang, Ye Chen, Renpeng Li, You Zhai, Yuanhao Chang, Wei Zhang, Fang Yuan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cc0518cb292540428b7dba760c8cd2d2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients
por: Zenghui Qian, et al.
Publicado: (2021) -
Identification of Methylation Immune Subtypes and Establishment of a Prognostic Signature for Gliomas Using Immune-Related Genes
por: Zhengang Hu, et al.
Publicado: (2021) -
Curcumin and Radiotherapy Exert Synergistic Anti-Glioma Effect In Vitro
por: Vasiliki Zoi, et al.
Publicado: (2021) -
A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma
por: Sun P, et al.
Publicado: (2021) -
Development and Verification of the Amino Metabolism-Related and Immune-Associated Prognosis Signature in Gliomas
por: Yang Xu, et al.
Publicado: (2021)